Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19163805 | 0.86 | CHRNA7 (0.35) | CHRNA7DPP4DPP8DPP7HSD11B1 | |
| SCHEMBL21672529 | 0.84 | DPP4 (0.32) | DPP4DPP8DPP7HSD11B1 | |
| SCHEMBL19163827 | 0.84 | DPP4 (0.39) | DPP4DPP8DPP7HRH3KCNH2 | |
| SCHEMBL19171208 | 0.77 | MAOA (0.44) | HSD11B1 | |
| SCHEMBL19171366 | 0.71 | ALDH1A1 (0.36) | CHRNA7PIK3R1PIK3CAKDM4EALDH1A1 | |
| SCHEMBL19163776 | 0.71 | HRH3 (0.37) | CHRNA7HRH3KCNH2KDM4EALDH1A1 | |
| SCHEMBL24329407 | 0.69 | AADAT (0.33) | CHRNA7HRH3PIK3R1PIK3CA | |
| SCHEMBL17993866 | 0.69 | HRH3 (0.34) | CHRNA7HRH3KDM4EALDH1A1LMNA | |
| SCHEMBL19164014 | 0.69 | NAMPT (0.35) | CHRNA7HRH3PIK3R1PIK3CA | |
| SCHEMBL19164231 | 0.69 | TLR9 (0.32) | CHRNA7HRH3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CHRNA7 3197/4885DPP4 2497/4885DPP8 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.